TY - JOUR
T1 - Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow
AU - Gulati, S.
AU - Acaba, L.
AU - Yahalom, J.
AU - Reich, L.
AU - Motzer, R.
AU - Crown, J.
AU - Doherty, M.
AU - Clarkson, B.
AU - Berman, E.
AU - Atzpodien, J.
AU - Andreeff, M.
AU - Gee, T.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1992
Y1 - 1992
N2 - Thirty adult patients with acute myelogenous leukemia (AML) in remission were treated with hyperfractionated total body irradiation, VP-16, and cyclophosphamide followed by infusion of autologous bone marrow purged with 4-hydroperoxycyclophosphamide and VP-16. Fifteen patients were transplanted in first remission (R1), 13 in second remission (R2), and two in third remission (R3). All patients had hematopoietic engraftment. The median time to achieve a white blood cell count of 1.0 x 109/l and a neutrophil count of 500 x 106/l was 32 days. The median time to achieve an unsupported platelet count of 50 x 109/l was 70 days. There were four transplant-related deaths, all in patients in R2. Ten patients have relapsed, including both patients transplanted in R3. The disease-free survival (DFS) of all patients is 52%, median follow-up not yet reached. Although the number of patients in each group is small and follow-up is limited, there is a trend toward improved actuarial DFS in patients transplanted in R1 compared with patients transplanted in R2 (72 vs 39%; p = 0.081). Use of VP-16 in the conditioning regimen as well as in the purging procedure is feasible in the treatment of patients with AML.
AB - Thirty adult patients with acute myelogenous leukemia (AML) in remission were treated with hyperfractionated total body irradiation, VP-16, and cyclophosphamide followed by infusion of autologous bone marrow purged with 4-hydroperoxycyclophosphamide and VP-16. Fifteen patients were transplanted in first remission (R1), 13 in second remission (R2), and two in third remission (R3). All patients had hematopoietic engraftment. The median time to achieve a white blood cell count of 1.0 x 109/l and a neutrophil count of 500 x 106/l was 32 days. The median time to achieve an unsupported platelet count of 50 x 109/l was 70 days. There were four transplant-related deaths, all in patients in R2. Ten patients have relapsed, including both patients transplanted in R3. The disease-free survival (DFS) of all patients is 52%, median follow-up not yet reached. Although the number of patients in each group is small and follow-up is limited, there is a trend toward improved actuarial DFS in patients transplanted in R1 compared with patients transplanted in R2 (72 vs 39%; p = 0.081). Use of VP-16 in the conditioning regimen as well as in the purging procedure is feasible in the treatment of patients with AML.
UR - http://www.scopus.com/inward/record.url?scp=0026641745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026641745&partnerID=8YFLogxK
M3 - Article
C2 - 1525601
AN - SCOPUS:0026641745
SN - 0268-3369
VL - 10
SP - 129
EP - 134
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 2
ER -